Fig. 1. Change in best-corrected visual acuity (BCVA). Mean logarithm of the minimal angle of resolution (logMAR, visual acuity) significantly improved after treatment with ranibizumab or bevacizumab from baseline to 6 months (*significantly different from baseline, p < 0.05). IVL = ranibizumab; IVA = bevacizumab.
